secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001664710-25-000025
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics amends bylaws to update director nomination procedures, universal proxy rules
--------------------------------------------------------------------------------

- Updated advance notice provisions for director nominations, including requirements under Rule 14a-19 and limiting nominees to board seats available.
- Enhanced disclosure requirements for nominating stockholders and nominees, with obligation to update and supplement information.
- Clarified procedures for stockholder meetings, including meeting place, adjournment, notices, conduct, and stockholder lists.
- Conforming edits and other clarifying updates to improve consistency across bylaws.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000025/0001664710-25-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000025/kros-20250305.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer